Azenta Inc Stock Price, News & Analysis

Azenta's GENEWIZ is celebrating its 25th anniversary with the launch of GENEWIZ Week from September 16-20, 2024. This event showcases GENEWIZ's commitment to advancing scientific discoveries through cutting-edge solutions. The week-long celebration includes:

• Virtual workshops followed by interactive expert roundtables
• An awards program offering $50,000 in research funding
• Engaging promotions and giveaways

The event aims to support researchers in overcoming challenges and streamlining their work. Ginger Zhou, SVP & GM of GENEWIZ Multiomics and Synthesis Solutions, emphasized the company's dedication to providing tools and support for significant scientific discoveries. Registration for GENEWIZ Week 2024 is now open, offering researchers opportunities for learning, networking, and celebration.

Azenta (Nasdaq: AZTA) reported its third-quarter results for fiscal 2024, ending June 30, 2024. The company achieved revenue of $173 million, up 4% YoY, driven by growth in Sample Management Solutions and B Medical Systems. Organic revenue grew by 5% YoY. Non-GAAP diluted EPS from continuing operations increased to $0.16 from $0.13. Adjusted EBITDA rose 39% to $18 million, with a margin of 10.3%. The company repurchased 4.2 million shares for $225.9 million. Azenta revised its FY2024 guidance, lowering revenue expectations to $652-$658 million but raising earnings guidance to $0.30-$0.36 per share. Operating cash flow was $2 million, and the company had $754 million in cash and equivalents at the quarter's end. The company will host an earnings call, accessible on its investor relations website.

Azenta (Nasdaq: AZTA) has announced its participation in the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference. The event is scheduled for Monday, August 12, 2024. This conference provides a platform for companies in the medical technology and diagnostics sectors to engage with investors and industry professionals.

The virtual format of the conference allows for efficient one-on-one meetings between company management and attendees. Azenta's participation suggests its commitment to maintaining investor relations and showcasing its position in the MedTech and diagnostics markets. This event could offer insights into Azenta's strategies, recent developments, and future outlook in the rapidly evolving healthcare technology landscape.

Azenta (Nasdaq: AZTA) is set to announce its fiscal third quarter 2024 earnings on Tuesday, August 6, 2024, after the market closes. The earnings pertain to the quarter ending on June 30, 2024. The company will also host a conference call and live webcast to discuss the financial results at 4:30 p.m. Eastern Time on the same day. Interested parties, including analysts, investors, and media, can access the live webcast through the Azenta website. Additionally, a replay of the webcast will be available starting at 8:30 a.m. ET on August 7, 2024.

Azenta (Nasdaq: AZTA) has announced its participation in the FinnGen project, a large-scale personalized medicine initiative in Finland. Azenta will provide proteomics profiling for up to 20,000 individuals out of the 500,000 Finnish biobank participants in the study. The company will use Olink's advanced proteomics technology to deliver high-quality protein-level measurements across major biological pathways.

This collaboration with the University of Helsinki aims to integrate proteomics insights with extensive genomic data, potentially leading to a deeper understanding of disease mechanisms, new biomarkers for early detection, and novel therapeutic targets. Azenta's involvement underscores its commitment to advancing healthcare innovation and personalized treatments.

Azenta (Nasdaq: AZTA) has been chosen by the Crohn's & Colitis Foundation for sample management services for two key research initiatives: CAPTURE IBD and IBD SIRQC. These studies focus on pediatric and surgical care for Crohn's disease and ulcerative colitis. Azenta will handle sample processing, analysis, logistics, and storage. These efforts are part of the Foundation's IBD Plexus® platform, which aims to revolutionize research with well-phenotyped data and biosamples. CAPTURE IBD is a longitudinal study enrolling thousands of pediatric patients across 12 U.S. sites. IBD SIRQC targets 5,000 patients at 9 sites, focusing on surgical outcomes. Azenta's role is anticipated to advance understanding and treatment of these diseases.

Azenta (Nasdaq: AZTA) announced its participation in the Jefferies Global Healthcare Conference in New York on June 5, 2024. The company's presentation will start at 11:00 am ET. A live webcast and a replay will be accessible on Azenta's investor relations website. This event is significant for sharing strategic updates and potential investor engagement.

Azenta has inaugurated a new Genomics Laboratory in Oxford, UK, enhancing its global GENEWIZ Multiomics & Synthesis Solutions. This facility provides UK researchers with advanced NGS platforms and local scientific expertise. The lab aims to expedite high-quality data delivery, fostering progress in critical research areas like diabetes, infectious diseases, and Alzheimer's. The lab features state-of-the-art technology from Illumina, PacBio, Oxford Nanopore, and more. It offers a comprehensive suite of services including library preparation, sequencing, and bioinformatics, supported by Ph.D.-level managers. The opening event on April 25, 2024, included a ribbon-cutting ceremony and lab tour.

Azenta, Inc. (Nasdaq: AZTA) announced a CEO succession plan with CEO Dr. Stephen Schwartz retiring after over 14 years of service. The Board is actively searching for a successor with the help of a leading executive search firm. Dr. Schwartz expressed pride in Azenta's transformation into a leading life sciences business and supports a smooth transition to the new CEO. Azenta also reported its earnings results for the second quarter of fiscal 2024.